Dymista No Menu

References

Carr W, Bernstein J, Lieberman P et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-89. 

Meltzer E, Ratner P, Bachert C et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

ARIA guidelines 2010, kortversjon

Ref: Dymista® SPC (31.05.2018), avsnitt 2

Bousquet J, Meltzer E, Couroux P et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber, J Allergy Clin Immunol Pract 2018;6(5):1726-1732

 

 

Ref: Dymista® SPC (31.05.2018), avsnitt 6.5

Price D, Shah S, Bhatia S et al. A New Therapy (MP29-02) Is Effective for the Long-Term Treatment of Chronic Rhinitis. J Investig Allergol Clin Immunol 2013;Vol.23(7):495-503.

Ref: Dymista® SPC (31.05.2018), avsnitt 4.2

Bousquet J, Demoly P, Devillier P et al. Impact of Allergic Rhinitis Symptoms on Quality of Life in Primary Care. Int Arch Allergy Immunol 2013;160:393-400.

Berger WE, Shah S, Lieberman P et al. Long-term, randomized Safety Study of MP29-02 (a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate in an Advanced Delivery System) in Subject With Chronic Rhinitis. J Allergy Clin Immunol Pract 2014;2(2):179-85.

Meltzer E, Ratner P, Bachert C et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

Meltzer E, Ratner P, Bachert C et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

Produktresumé: www.fass.se

 

Meltzer E, Ratner P, Bachert C et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

Carr W, Bernstein J, Lieberman P et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-89.

Leung DYM, Szefler SJ et al. MP29-02: a major advancement in the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129:1216.

SPC: Felleskatalogen.no/medisin/spc-dymista-meda-580737

Meltzer et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77

Carr W, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-89.

Produktresumé: www.fass.se

Meltzer et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

Price et al. Short and long-term safety of MP29-02: a new therapy for the treatment of allergic rhinitis. Presented at SERIN, Leuven, March 21-23, 2013.

Produktresuméwww.fass.se

Bousquet PJ et al. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol 2013;160:393-400.

Price D et al. Sub-optimal control of allergic rhinitis: the need for a new and more effective treatment option. Presented at EAACI, Milan, June 22-26, 2013.

Ref: Dymista® SPC (31.05.2018), avsnitt 4.1

Produktresumé: www.fass.se

Meltzer et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

Produktresumé: www.fass.se

Price et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol 2013;In press].

Meltzer et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

Carr W, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-89.

Leung et al. MP29-02: a major advancement in the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129:1216.

Meltzer E, Ratner P, Bachert C et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

Canonica GW, Bousquet J, Mullol J et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62(Suppl 85):17-25.

Leung et al. MP29-02: a major advancement in the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129:1216.

Meltzer et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

Meltzer E, Ratner P, Bachert C et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

Meltzer et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

Meltzer et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77

Canonica GW, Bousquet J, Mullol J et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62(Suppl 85):17-25.

Meltzer E, Ratner P, Bachert C et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

Meltzer et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

Carr W, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-89.

Leung et al. MP29-02: a major advancement in the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129:121.

Meltzer et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

Carr W, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-89.

Price et al. Short and long-term safety of MP29-02: a new therapy for the treatment of allergic rhinitis. Presented at SERIN, Leuven, March 21-23, 2013.

Price et al. MP29-02 a novel intranasal therapy for the treatment of chronic rhinitis: safety data from a 12 month trial. Presented at EAACI, Geneva, June 16-20, 2012.

Carr W, Bernstein J, Lieberman P et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-89.

Price D et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol 2013;in press

Price D et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol 2013;in press

Prof David Price, Professor of Primary Care Respiratory Medicine

Prof Jean Bousquet
Chairman of ARIA Guidelines

Dr Eliz Meltzer
Recipient of AAAAI Distinguished Clinician Award

Dr Glenis Scadding
Past President of BSACI

Dr Dermot Ryan
Chair of EAACI Primary Care Group

Prof Ulrich Wahn
Paediatr Pneumonology & Immunology, Charite, Berlin

Prof Phil Lieberman
Former President of AAAAI

Prof Ronald Dahl
Past President of European Respiratory Society

Prof David Price
Professor of Primary Care Respiratory Medicine

Prof David Price
Professor of Primary Care Respiratory Medicine

Dr Alina Dumitru
Allergy Specialist, Royal Brompton, London

Prof Edward Kaminski
Consultant Immunologist, Plymouth

Expert Dr Michael Kaliner, former President of WAO

Canonica GW et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62(Suppl 85):17-25

Logg inn

Logga in

StängStäng

Sign in to Dymista

Don't have a Dymista account?

Vi gjør oppmerksom på at informasjonen om reseptpliktige legemidler er tilrettelagt for helsepersonell.

Er du helsepersonell?

Ja Nei

No, I am not a HCP

Sorry, you do not have the authorization to enter this webpage.

Go back Go back
close-icon